louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05529329: Zirconia Versus Lithium Di-silicate Overlays for Restoring Hypomineralized Molars Affected With MIH
Official title: Clinical Outcome of Zirconia Versus Lithium Di-silicate Overlays Restorations for Restoring Vital Young Permanent First Molar Teeth Affected With Moderate Form of Molar Incisor Hypomineralization: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Molar Incisor Hypomineralization
Keywords: MIH - zironia - Lithium Disilicate - Overlays
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2022-09-07
Enrollment: 52
Sex: ALL
Minimum age (years): 7
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized Clinical Trial
Primary purpose: TREATMENT

Brief summary: the study evaluate the clinical outcome of zirconia versus lithium disilicate overlays restorations for restoring vital young permanent first molar teeth affected with moderate form of molar Incisor hypomineralization: randomized clinical trial.

Detailed description: To compare the one-year clinical outcome of zirconia versus lithium disilicate overlays restorations. Materials and methods: Twenty patients were distributed into two groups in relation to the material used for the fabrication of overlays restorations; group (Z) (n=10): patients received zirconia restorations, group (EC): patients received IPS E.max Cad restorations. Clinical and radiographic evaluations of these restorations were carried out at base line (1 week), 3, 6 and 12 months after cementation using FDI World Dental Federation criteria

Eligibility criteria: Inclusion Criteria:

* Children's age ranging from 10 to 15 years old.
* Existence of large carious lesion in young permanent first molar teeth associated with weak cusps.
* Signs of vital pulp without symptoms of pulpitis.
* Presence of antagonists and adjacent teeth and occlusal contacts with good level of oral hygiene.
* Children should be able to physically and psychologically tolerate conventional restorative procedures.

Exclusion Criteria:

* Children with poor oral hygiene and symptoms of pulpitis.
* Children suffer from parafunctional habits.
* Children with any debilitating systemic disorder.

Primary outcomes:
measure: Clinical Outcome
timeFrame: one year
measure: Restoration Evaluation
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al-Azhar University
state: Naser City
Study officials:
affiliation: Al-Azhar University- faculty of dentistry
name: alaa F mohammed, Ph. D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04044729: Mechanisms of CBD for Chronic Pain
Official title: Exploring the Mechanisms Underlying the Analgesic Properties of Cannabidiol Using Magnetic Resonance Spectroscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Chronic Pain
Lead sponsor: University of Utah
Sponsor class: OTHER
First posted: 2019-08-05
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a study designed to examine the neurochemical mechanisms associated with Cannabidiol (CBD) versus placebo for chronic non-cancer pain.

Detailed description: The aim of this trial is to examine the neurochemical mechanisms associated with Cannabidiol (CBD) versus placebo for chronic non-cancer pain. Participants will include individuals with chronic pain, who will be randomized into one of two intervention conditions: low THC/high CBD or placebo. In addition to receiving CBD or placebo, participants also will complete symptom assessments of chronic pain data (intensity, quality, interference/disability) throughout the study. These measures will be gathered prior to and following the fifth doses (dosing will occur once per day for five days) of CBD or placebo. A secondary objective will be to examine the association between clinical and inflammatory markers.

Eligibility criteria: Inclusion Criteria:

* Age between 18-50 yrs.
* Chronic musculoskeletal and joint pain for at least 3 months or longer.
* Participants must live within a 60 mile radius of Salt Lake City, Utah to be eligible.

Exclusion Criteria:

* Current or past neurological illness.
* Substance abuse or dependence within the prior 90 days.
* Contraindication to brain MRI.
* Type I and type II diabetes.
* Unstable medical conditions.
* Consumption of more than 2 drinks of alcohol per night.
* Current pregnancy or planning to become pregnant or breastfeeding.
* History of seizures or head trauma at PI discretion.
* Active or history of major mental illness
* Use of opioid medications in the past 30 days.
* LFT results 3 times greater than the upper limit of normal at the screening.
* Participants may be excluded if the PI feels they do not meet safety criteria.

Primary outcomes:
measure: Neurochemical Brain Changes
timeFrame: 5 Days
Secondary outcomes:
measure: Pain Improvement
timeFrame: 7 Days
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: University Of Utah
state: Utah
Study officials:
References:
Clinical trial NCT01283529: Reference Values for Pulse Induced Continuous Cardiac Output (PiCCO) Variables in Children
Official title: Reference Values for Cardiac Output and Blood Volume Variables in Children With Normal Cardiac Function Measured Under General Anesthesia.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Reference Values
Keywords: Intrathoracal blood volume
Cardiac output
Children
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2011-01-26
Enrollment: 31
Sex: ALL
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 40 children age 0 - 15 years undergoing major neurosurgery under general anesthesia

Brief summary: Pulse induced continuous cardiac output (PiCCO) is an established technology for measurement of advanced hemodynamic variables in critically ill patients. PiCCO is approved and designed also for use in children, but there is a lack of documentation of reference values in children not suffering from a critical illness. The goal of this study is to establish such values.


Eligibility criteria: Inclusion Criteria:

* Age \< 15 years
* Scheduled for major neurosurgery in general anesthesia

Exclusion Criteria:

* Cardiac disease
* Infection / sepsis

Primary outcomes:
measure: Reference values for PiCCO variables
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital, Rikshospitalet
Study officials:
affiliation: Oslo University Hospital
name: Gunnar Bentsen, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01841229: Effect of Ginseng on Glycemic Control
Official title: Effect of Ginseng on Glycemic Control: A Systematic Review and Meta-analysis of Controlled Trials to Provide Evidence-based Clinical Recommendations
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Impaired Glucose Tolerance
Diabetes
Lead sponsor: Unity Health Toronto
Sponsor class: OTHER
First posted: 2013-04-26
Enrollment: 770
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Sampling method: PROBABILITY_SAMPLE
Study population: Diabetic (type 1 \& type 2) Pre-diabetic Hypertensive Healthy

Brief summary: Ginseng (American ginseng, Asian ginseng, Korean ginseng etc) is expected to show positive hypoglycemic effects, including improvements in glycated blood proteins\[HbA1c\], fasting glucose, fasting insulin, and the homeostasis model assessment of insulin resistance \[HOMA-IR\]).

Detailed description: Ginseng has demonstrated to have significant hypoglycemic effect. Its major pharmacological component is considered to be ginsenosides. Several trials have been undertaken in diabetes some of which have demonstrated advantages in glycemic control in both diabetic as well as non diabetic individuals although clinical consistency of results is lacking.The lack of high quality data in this area to support diabetes recommendations represents an urgent call for stronger evidence. A systematic review and meta-analysis of controlled trials remains the "Gold Standard" of evidence for recommendations and clinical guidelines development. Therefore, investigators will conduct a systematic review and meta-analyses of controlled trials to assess the effect of ginseng on glycemic control.

Eligibility criteria: Inclusion Criteria:

* Dietary trials in humans
* Randomized treatment allocation
* 1 month
* Suitable control
* Viable endpoint data

Exclusion Criteria:

* Non-human studies
* Non-randomized treatment allocation
* \<1 month
* Lack of a suitable control
* No viable endpoint data

Primary outcomes:
measure: Glycated hemoglobin (HbA1c)
timeFrame: 1month
Secondary outcomes:
measure: Fasting blood glucose
timeFrame: 1month
measure: Fasting plasma insulin
timeFrame: 1 month
measure: Homeostasis model assessment of insulin resistance (HOMA-IR)
timeFrame: 1 month
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: The Toronto 3D Knowledge Synthesis and Clinical trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St.Michael's Hospital.
state: Ontario
Study officials:
affiliation: Unity Health Toronto
name: Vladimir Vuksan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Shishtar E, Sievenpiper JL, Djedovic V, Cozma AI, Ha V, Jayalath VH, Jenkins DJ, Meija SB, de Souza RJ, Jovanovski E, Vuksan V. The effect of ginseng (the genus panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials. PLoS One. 2014 Sep 29;9(9):e107391. doi: 10.1371/journal.pone.0107391. eCollection 2014.
Clinical trial NCT06279429: Sucrosomial Iron on Insomnia in Non-dialysis Chronic Kidney Disease Patients With Iron Deficiency Anemia
Official title: Sucrosomial Iron on Insomnia in Non-dialysis Chronic Kidney Disease Patients With Iron Deficiency Anemia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: CKD
Sleep Disorder
Lead sponsor: Kuang Tien General Hospital
Sponsor class: OTHER
First posted: 2024-02-28
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Insomnia or sleep disturbance is a common disorder in patients with chronic kidney disease (CKD), but is often unrecognized and undertreated. It is known that sleep disorders may indirectly cause a variety of diseases and affect quality of life. The most common sleep disorders that occur in CKD are insomnia, excessive daytime sleepiness, obstructive or central sleep apnea (SA), and sleep disorders. This study evaluates the effectiveness and safety of Sideral® Sucrosomial Iron and iron chewable tablets 100mg commonly used in health insurance on sleep disorders in patients with CKD and iron deficiency anemia.


Eligibility criteria: Inclusion Criteria:

1. Adults aged 20-80.
2. Chronic kidney disease (CKD) patients.
3. Iron deficiency anemia (male haemoglobin (Hb) ≤13 g/dL; female haemoglobin (Hb) ≤12 g/dL, ferritin ≤100 ng/mL, transferrin saturation ≤25%).
4. Patients diagnosed as chronic insomnia by doctors according to international classification of sleep disorders-third edition (ICSD-3).
5. Subjects who voluntarily participate in the trial plan and complete the consent form after explanation by doctors or project personnel.

Exclusion Criteria:

1. Patients taking iron supplements.
2. Patients with non-chronic insomnia.
3. Patients with alcoholism within one year.
4. People with other serious diseases.
5. Pregnant women or women who are still breastfeeding.
6. Those who are unable to cooperate with the test progress.
7. Patients with autoimmune abnormalities (ex. inflammatory bowel disease).
8. People with non-iron deficiency anemia (ex. thalassemia).
9. Those who are taking sleeping pills or sedatives.

Primary outcomes:
measure: Insomnia Severity Index (ISI)
timeFrame: week 0, 12
measure: Pittsburgh Sleep Quality Index (PSQI)
timeFrame: week 0, 12
measure: Epworth sleepiness Scale (ESS)
timeFrame: week 0, 12
measure: Hemoglobin
timeFrame: week 0, 12
measure: Ferritin
timeFrame: week 0, 12
measure: Serum Iron
timeFrame: week 0, 12
measure: Transferrin Saturation
timeFrame: week 0, 12
measure: Erythrocyte sedimentation rate
timeFrame: week 0, 12
Secondary outcomes:
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Kuang Tien General Hospital
Study officials:
affiliation: Chief, Department of Neurology
name: Chun-Pai Yang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00002029: Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent
Official title: Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Keywords: Weight Loss
Parenteral Nutrition, Total
AIDS-Related Opportunistic Infections
Liposyn
Acquired Immunodeficiency Syndrome
Lead sponsor: Abbott
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To compare two lipid emulsions in the long-term parenteral alimentation of patients with AIDS in relation to: Clinical effectiveness. Effect on immunologic function. Effect on HIV load as measured by p24 antigen levels. Effect on relative HIV infectivity.


Eligibility criteria: Inclusion Criteria

Concurrent Medication:

Allowed:

* Zidovudine (AZT).
* All drugs used for the standard treatment of opportunistic infections.
* Other drugs used for the treatment of other AIDS conditions if they have been started more than 3 months prior to study entry.

Patients must have:

* Diagnosis of AIDS.
* Weight loss of \> 10 percent premorbid body weight.
* Presenting diagnosis of either opportunistic infection or Kaposi's sarcoma.
* Require home total parenteral nutrition (TPN) for a period of approximately 3 months.
* Life expectancy = or \> 90 days.

Prior Medication:

Allowed:

* Zidovudine (AZT).

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

* Life expectancy \< 90 days.
* Biliary stasis.
* History of drug abuse.

Patients with the following are excluded:

* Life expectancy \< 90 days.
* Biliary stasis.
* History of drug abuse.

Prior Medication:

Excluded within 3 months of study entry:

* Immunomodulators.
* Experimental antiviral DT. History of drug abuse.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Miami
country: United States
facility: Intracare Inc
state: Florida
city: East Orange
country: United States
facility: East Orange Veterans Administration Med Ctr
state: New Jersey
Study officials:
References:
citation: Singer P, Rubinstein A, Askanazi J, Calvelli T, Lazarus T, Kirvela O, Katz DP. Clinical and immunologic effects of lipid-based parenteral nutrition in AIDS. JPEN J Parenter Enteral Nutr. 1992 Mar-Apr;16(2):165-7. doi: 10.1177/0148607192016002165.
Clinical trial NCT00321529: Comparison of the ProAdjuster Analysis to the Penning Method of Determining Intersegmental Motion of the Cervical Spine
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cervical Spine Instability
Keywords: Cervical spine instability
Penning Study
Lead sponsor: Logan College of Chiropractic
Sponsor class: OTHER
First posted: 2006-05-03
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: RETROSPECTIVE

Brief summary: The purpose of this study is to determine if the ProAdjuster system of analysis can be used to determine cervical spine instability using the Penning system of radiographic marking as a standard of comparison.

Detailed description: This study will utilize the ProAdjuster Device as a method of assessing the motion of the cervical spine in participants with instability as determined by a Penning Radiographic analysis. Only participants with existing radiographic studies will be included in the study. No additional Radiographic will be required.

Eligibility criteria: Inclusion Criteria: Logan student, staff, or faculty with no history of ankle injury; 2. Age 18 - 60 yoa.

Exclusion Criteria: 1. Logan student, staff, or faculty ; 2. Local infection, injury or other malignancy affecting the cervical spine; 3. Any unstable joints of the cervical spine than require immobilization ; 4. Any manipulation to cervical spine within 48 hours; 5. Pregnancy.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Chesterfield
country: United States
facility: Logan College of Chiropractic
state: Missouri
Study officials:
affiliation: Logan Chiropractic College
name: Dennis E. Enix, DC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04793529: Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study
Official title: Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Verruca Vulgaris
Involucrin
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2021-03-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Vitamin D3 plays important role in keratinocyte differentiation and had been used recently in verruca vulgaris. Aim of the work: To assess the expression of involucrin in verrucae vulgaris before and after injection of vitamin D3. Subjects and Methods: This study included 60 patients with verrucae vulgaris subjected to intralesional injection of vitamin D3 at three weeks interval for a maximum of five sessions. Immunohistochemical assessment of involucrin was done before and after injection and compared to skin biopsies from 30 healthy individuals


Eligibility criteria: Inclusion criteria:

Patients with multiple verruca vulgaris Patients with with verrucae vulgaris with size more than 3 cm

Exclusion Criteria:

Patients with a past history of allergic response to vitamin D. Pregnant or lactating females. Hepatic patients. Renal patients. Patients with bleeding tendency.

Primary outcomes:
measure: Resolution of verrucae
timeFrame: 3 months
Secondary outcomes:
measure: Involucrin expression
timeFrame: 3 months
Other outcomes:
Locations:
city: Banhā
country: Egypt
facility: Essam Mohamed El-sayed Akl
Study officials:
References:
Clinical trial NCT04887129: Testing for COVID-19 in High Risk Children With Intellectual and Developmental Disabilities (COV-IDD)
Official title: COV-IDD: Testing for COVID-19 in High Risk Children With Intellectual and Developmental Disabilities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Covid19
Lead sponsor: University of Rochester
Sponsor class: OTHER
Collaborators: name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted: 2021-05-14
Enrollment: 392
Sex: ALL
Minimum age (years): 3
Maximum age (years): 72
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to understand how to prevent COVID-19 spread in a school like the Mary Cariola Center (MCC) in Rochester, NY by answering questions like these: how do activities in the school alter chances of infection? Are there people infected with the COVID-19 virus who have no symptoms? How is spread of COVID-19 affected by vaccination rates? Is there any hesitancy to get the vaccine and what are the reasons? This information will be used to help keep the school open and the students and staff safe.

Eligible participants are those that work at the Mary Cariola Center (MCC) and interact with the students at MCC who have a high risk of infection from COVID-19.

The study lasts for up to 16 months.


Eligibility criteria: Inclusion Criteria:

Students:

* IDD Student of the Mary Cariola Center
* Age 3 - 18
* Have a parent/guardian who can give informed consent
* In the judgement of the Mary Cariola Medical Staff will be able to safely participate in the study procedures (nasal swab, phlebotomy)

Staff

* Age 18 - 72
* Able give informed consent
* Anticipated duration of remaining employment less than 1 month (e.g. retiring)
* Must be willing to participate in RT-PCR and antibody testing

Exclusion Criteria:

Students

* Contraindication to nasal swab
* Contraindication to phlebotomy (e.g. anticoagulated, bleeding diathesis)

Staff

* Contraindication to nasal swab
* Contraindication to phlebotomy (e.g. anticoagulated, bleeding diathesis)

Primary outcomes:
measure: Number Infected With COVID-19
timeFrame: 16 months
measure: Change in the Percentage of Participants Reporting Anxiety
timeFrame: baseline to 16 months
measure: Change in the Percentage of Participants Classified as Depressed
timeFrame: baseline to 16 months
measure: Change in the Percentage of Participants Classified With Fatigue
timeFrame: baseline to 16 months
measure: Change in Percentage of Participants With Deficits in Social Functioning
timeFrame: baseline to 16 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mary Cariola Center
state: New York
Study officials:
References: